TII
25.5.2023 11:48:28 CEST | Business Wire | Press release
The Technology Innovation Institute (TII), a leading global scientific research center and the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), today strengthened its growing international influence in the field of artificial intelligence by announcing that "Falcon 40B," the UAE's first large-scale AI model, is now open source for research and commercial use. This pioneering move demonstrates Abu Dhabi's commitment to fostering collaboration across sectors and driving advancements in generative AI.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230525005043/en/
"Falcon 40B," the UAE's first large-scale AI model, is now open source for research and commercial use. (Photo: AETOSWire)
Falcon, a foundational large language model (LLM) with 40 billion parameters, trained on one trillion tokens, grants unprecedented access to researchers and small and medium-sized enterprise (SME) innovators alike. TII is providing access to the model’s weights as a more comprehensive open-source package, with the aim of enabling access to powerful LLM capabilities, promoting transparency and accountability, and supporting innovation and research in the field.
In the current AI ecosystem, developers are finding LLMs that provide access to model weights more appealing due to the enhanced capabilities they offer for fine-tuning compared to those without. While the majority of LLMs have granted exclusive licenses solely to non-commercial users, TII has taken a key stride in offering researchers and commercial users access to the Falcon 40B LLM.
In conjunction with the release of Falcon 40B as an open-source model, TII has launched a call for proposals, inviting scientists, researchers, and visionaries who are enthusiastic about harnessing the potential of the foundation model. They are encouraged to contribute their innovative ideas and leverage the model to build inspiring use cases or explore further possibilities for its application to cover areas like engineering, healthcare, sustainability, coding, and much more.
As an incentive for exceptional research proposals, selected projects will receive “training compute power” in the form of investment, enabling innovators to leverage robust computational resources for accelerated data analysis, complex modeling, and new discoveries. This support will nurture and accelerate the development of novel ideas, providing the necessary resources to turn them into impactful AI solutions with commercial viability and societal benefits.
VentureOne, the commercialization arm of ATRC, will facilitate computation power to productize the most innovative solutions.
"Making Falcon 40B open source represents a critical milestone in our commitment to fostering AI innovation," said H.E.Faisal Al Bannai, Secretary General of the Advanced Technology Research Council (ATRC). "We are disrupting LLM access and enabling researchers and entrepreneurs to come up with the most innovative use cases. We will further support these submissions with computation power as funding through VentureOne, helping to advance a thriving research ecosystem.”
Falcon, first unveiled in March 2023, showcased exceptional performance and underscored the UAE's commitment to technological progress. Based on Stanford University’s HELM LLM benchmarking tool, Falcon 40B outperformed its renowned counterparts in utilizing significantly less training compute power. With only 75 percent of the training compute of OpenAI's GPT-3, 40 percent of DeepMind's Chinchilla AI, and 80 percent of the training compute of Google's PaLM-62B, the tool substantiated TII's commitment to advancing developments in generative AI.
Dr. Ray O. Johnson, CEO of TII, said: "Computing power plays a pivotal role in expediting AI system training and enabling faster implementation of use cases. As the new fuel that drives technological innovation, the move to offer such support will be game-changing in enhancing the capabilities of innovators, and enabling them to push the boundaries of their projects to achieve remarkable advancements."
Falcon 40B is a breakthrough led by TII’s AI and Digital Science Research Center (AIDRC). The same team also launched NOOR, the world’s largest Arabic NLP model last year, and is on track to develop and announce Falcon 180B soon.
Dr. Ebtesam Almazrouei Director, AI Cross-Center Unit, TII, said: “The open-source release of Falcon 40B, 7.5B, and 1.3B parameter AI models and our high-quality REFINEDWEB dataset, exemplifies the profound scientific contributions of the UAE. With each breakthrough, we defy limitations, reshape the realm of possibilities, and pave the way for collaborative efforts with transformative impact."
The UAE recently moved up five places to rank as the top Arab country and the 37th out of 166 countries in the UN Frontier Technologies Readiness Index 2023. Complementing a long list of progressive technology milestones, the open-source generative AI model is set to boost the UAE’s credentials as a mainstream AI player.
If you are interested in accessing the Falcon AI models or submitting for the use case call for proposal, we invite you to visit FalconLLM.TII.ae. Falcon LLMs open sourced to date, will be made available under a license built upon the principles of open-source Apache 2.0 software, which allows for a wide range of free use.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230525005043/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 08:07:00 CET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 08:00:00 CET | Press release
CE Marking enables marketing and clinical use of the world’s first and only LINAC vault-ready proton therapy system across the European Union Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers a
Bureau Veritas:Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 07:30:00 CET | Press release
Strong margin improvement to 16.3% in FY 2025Positive growth outlook with continued margin expansion in 2026New EUR 200 million share buyback Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 07:00:00 CET | Press release
Regulatory authorities in the European Union (EU), the United States (U.S.), and Canada have approved a new state-of-the-art Restylane®syringe for use with a range of Restylane NASHA® lidocaine products in multiple indications in the face and in the hands1-3 Developed in collaboration with aesthetic practitioners, its innovative ergonomic design features a cushioned finger grip and thumb rest, to improve practitioner experience through better injection comfort and control, helping them deliver consistently premium results 4-7 The syringe’s carton packaging is the first in the industry to be made from 100% recyclable paper, and reaffirms Galderma’s commitment to sustainability and environmental responsibility 8 These approvals demonstrate Galderma’s strong heritage in Injectable Aesthetics, and its commitment to continuing to drive innovation in the field Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-ar
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 07:00:00 CET | Press release
Preclinical proof-of-concept data in GM2 gangliosidosis demonstrated survival benefit, functional improvement and target engagementResults are published in the 7 January issue of the Journal of Inherited Metabolic DiseaseNizubaglustat is currently in Phase 3 registrational studies in GM1/GM2 gangliosidoses and Niemann-Pick type C disease (NPC) Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom